Targeting Oncogenic KRAS in Non-Small-Cell Lung Cancer

SIMPLE SUMMARY: v-Ki-ras2 Kirsten rat sarcoma viral oncogene (KRAS) is the most common driver in NSCLC, and targeting oncogenic KRAS is a major challenge in the treatment of non-small-cell lung cancer (NSCLC). While several covalent KRAS G12C inhibitors have emerged as a novel anti-KRAS therapy, the...

Descripción completa

Detalles Bibliográficos
Autores principales: Sunaga, Noriaki, Miura, Yosuke, Kasahara, Norimitsu, Sakurai, Reiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8656763/
https://www.ncbi.nlm.nih.gov/pubmed/34885068
http://dx.doi.org/10.3390/cancers13235956

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8656763/
https://www.ncbi.nlm.nih.gov/pubmed/34885068
http://dx.doi.org/10.3390/cancers13235956

Ejemplares similares